de Sèze

Research interests

Publications

• Diagnosis and classification of optic neuritis

  The Lancet Neurology · 2022 · https://doi.org/10.1016/s1474-4422(22)00200-9

• Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01318-5

• Myelin-oligodendrocyte glycoprotein antibody-associated disease

  The Lancet Neurology · 2021 · 10.1016/s1474-4422(21)00218-0

• Ofatumumab versus Teriflunomide in Multiple Sclerosis

  New England Journal of Medicine · 2020 · 10.1056/nejmoa1917246

• Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

  Radiology · 2020 · 10.1148/radiol.2020202222

• Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology

  Neurology Neuroimmunology & Neuroinflammation · 2020 · 10.1212/nxi.0000000000000841

• Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

  Annals of Neurology · 2020 · 10.1002/ana.25909

• Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study

  Radiology · 2020 · 10.1148/radiol.2020202222

• Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

  JAMA Neurology · 2020 · 10.1001/jamaneurol.2020.2581

• Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1901747

• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30475-6

• MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

  Journal of Neuroinflammation · 2018 · https://doi.org/10.1186/s12974-018-1144-2

• Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

  Neurology · 2018 · 10.1212/wnl.0000000000005560

• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1606468

• MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

  Multiple Sclerosis Journal · 2016 · 10.1177/1352458516667568

• MRI characteristics of neuromyelitis optica spectrum disorder

  Neurology · 2015 · 10.1212/wnl.0000000000001367

• Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography

  Multiple Sclerosis Journal · 2015 · 10.1177/1352458514567216

• MRI characteristics of neuromyelitis optica spectrum disorder

  Neurology · 2015 · 10.1212/wnl.0000000000001367

• International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

  Neurology · 2015 · https://doi.org/10.1212/wnl.0000000000001729

• Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event

  PLoS ONE · 2014 · 10.1371/journal.pone.0090509

• Treatment of neuromyelitis optica: Review and recommendations

  Multiple Sclerosis and Related Disorders · 2012 · 10.1016/j.msard.2012.06.002

• Neuromyelitis Optica and Non–Organ-Specific Autoimmunity

  Archives of Neurology · 2008 · 10.1001/archneurol.2007.17

• Neurologic Manifestations in Primary Sjögren Syndrome

  Medicine · 2004 · 10.1097/01.md.0000141099.53742.16

• Tibial Muscular Dystrophy Is a Titinopathy Caused by Mutations in TTN, the Gene Encoding the Giant Skeletal-Muscle Protein Titin

  The American Journal of Human Genetics · 2002 · 10.1086/342380

• [False profile of the pelvis. A new radiographic incidence for the study of the hip. Its use in dysplasias and different coxopathies].

  PubMed · 1961

Current projects

No projects listed.